2022/06/10 News Release Santen and UBE announces U.S. Food and Drug Administration accepts resubmission of NDA for STN1011700 / DE-117 (omidenepag isopropyl) for treating glaucoma and ocular hypertension
2022/05/28 IR News (Presentation and Q&A Transcript) Telephone Conference for the FY2021 Consolidated Results / FY2022 Consolidated Forecasts
2022/05/19 IR News "UBE Vision 2030 Transformation～1st Stage～" Management Overview Briefing (May 2022)
2022/05/19 IR News UBE Group Unveils New Medium-Term Management Plan "UBE Vision 2030 Transformation--1st Stage"
2022/05/12 IR News Telephone Conference for the FY2021 Consolidated Results / FY2022 Consolidated Forecasts
2022/04/28 News Release UBE Corporation Announces Change of Representative Director and Personnel Change
2022/04/12 News Release UBE Group Announces New Medium-Term Targets by 2030 for Achieving Carbon Neutrality by 2050
2022/04/07 News Release UBE Corporation Selected as a Constituent of FTSE Blossom Japan Sector Relative Index
2022/03/28 News Release Ube Industries and HiLung Sign Joint Development Agreement for Co-Development of Novel Selective LPA1 Antagonist HL001 for Pulmonary Fibrosis
2022/03/23 News Release Ube Industries and Kirilys Therapeutics, Inc. Sign License Agreement for CDK7 inhibitors
2022/02/28 News Release Shionogi and Ube Industries Enter into a Strategic Development Collaboration for the Novel Anti-RS Virus Drug Candidate S-337395
2022/02/04 IR News (Presentation and Q&A Transcript) Telephone Conference for the Third Quarter of FY2021 Consolidated Result
